Paralog Therapeutics
Paralog Therapeutics is a pre-clinical stage precision medicine company focused on the development of anti-cancer therapies. Paralog Therapeutics’ mission is to identify and leverage synthetic vulnerabilities in cancers that carry specific gene alterations.
-
Tiziana Parisi, PhD
CEO, CSO & Co-founder
-
Steen Hansen, PhD, MD
President & Academic Co-founder
State 4 Therapeutics
State 4 Therapeutics is developing oral small molecule therapies that synergize with nutrient-stimulated hormones for the treatment of obesity and metabolic diseases.
-
Dick Kibbey, MD, PhD
Scientific Founder
-
Matt Merrins, PhD
Scientific Founder
-
Ania Jastreboff, MD, PhD
Founder, Clinical Scientific Advisor
-
Robert Williams, PhD
Lead Operator
TMAB Therapeutics
TMAB Therapeutics is developing first-in-class multi-specific antibodies designed to enhance immune activation while inhibiting angiogenesis within the solid tumor microenvironment. By simultaneously targeting CD5L and EGLF6, TMAB Therapeutics aims to overcome adaptive resistance to anti-VEGF and anti-PD1 therapies, offering a novel treatment approach for non-small cell lung cancer, microsatellite-stable colorectal cancer, and high-grade serous epithelial…
-
Tinashe Chandauka, MD, PhD
Co-founder & CEO
-
Josh Sharan, DO
Co-founder & COO
TATUM Bioscience
Immuno-oncology, and the advent of checkpoint inhibitors, profoundly revolutionized the treatment of cancers by making cancer-free outcome a reality. Unfortunately, after more than a decade of drug development, only 20% of patients are responding to these blockbuster immunotherapies, which leaves 80% of patients without any therapeutic solutions. At TATUM bioscience we are dedicated to solving…
SiNON Nano Sciences
SiNON Nano Sciences is a biotechnology company pioneering carbon-based nanotechnology for targeted drug delivery, with a primary focus on Central Nervous System (CNS) diseases. Our patented Carbon Nano Particle (CNP) platform is designed to efficiently cross the blood-brain barrier (BBB), enabling safer, more precise, and highly effective treatment delivery for neurological disorders, oncology, and other…
-
Afreen Allam
CEO, MBA
Sebastian BioPharma
Sebastian BioPharma is a preclinical-stage biotechnology company driven by a singular mission: to develop groundbreaking biologics that offer new therapeutic options for millions of cancer patients. The company utilizes compelling proof-of-concept data from multiple innovative therapeutic strategies and a versatile ‘plug-and-play’ antibody-oligonucleotide conjugate (AOC) platform to enhance the efficacy of immune checkpoint blockade (ICB) therapies…
-
Greta Garrido, PhD
CEO & Co-Founder
-
Eli Gilboa, PhD
Inventor & Founder
OsteoCure Therapeutics, Inc
OsteoCure Therapeutics is a Duke University spinout and JLABS company focused on developing advanced therapies to address critical unmet needs in bone health and regeneration. Leveraging cutting-edge research, the company specializes in novel combination products designed to accelerate bone healing, mitigate pain, improve patient outcomes, and reduce recovery times for those suffering from orthopedic injuries…
-
Hunter Newman, PhD
Co-Founder and CEO
-
Shyni Varghese, PhD
Co-Founder and CTO
Lipo-Immuno Tech, LLC
Company Vision: To unite drug development, forward-thinking mechanistic science, and clinical application in order to create novel therapeutics that cure diseases. Overview: Lipo-ImmunoTech was founded on the goal of advancing anti-cancer strategies, which are also effective in treating some neurodegenerative disorders, like Alzheimer’s Disease, that have strong mechanistic data and can dramatically benefit patient health.…
-
Besim Ogretmen, PhD
Co-Founder and CEO, Lipo-Immuno Tech
-
Shikhar Mehrotra, PhD
Co-Founder and CSO, Lipo-ImmunoTech
Genicity Ltd
Genicity, founded in 2021 by Muhammad Yassin, MD, PhD, and Muneer Sawaied, MD, is an innovative Galway-based cell therapy company. Recognized with the Life Sciences and Healthcare Award at the Irish Times 2023 and the Merck Prize at the BioTech BootCamp, Genecity was also a finalist for the Golden Ticket from the American Cancer Society.…
-
Muhammad Yassin
MD, PhD Chief Scientific Officer, Co-Founder
-
Muneer Sawaied, MD
Chief Operating Officer, Co-Founder
D2B3
Over 98% of all drugs struggle to cross the Blood-Brain Barrier (BBB), hindering their usability against CNS diseases. D2B3’s breakthrough is a patented human monoclonal antibody (Mab), that transiently and highly specifically opens the BBB, achieving high drug penetration to the brain. The lead asset D2B3-01 has shown exceptional performance in in vivo proof of…
-
Manuel Mohr, PhD
Co-founder, Founding CEO
-
Anne Eichmann, PhD
Co-founder, Chief Scientific Advisor
-
Kevin Boyé, PhD
Co-founder, Lead Scientist/Advisor
HarborSite
HarborSite, a Harvard/Wyss Institute spinoff, is pioneering a safe and efficient gene insertion technology to provide curative treatments for rare genetic and common disorders. By engineering compact, simple yet potent enzymes — recombinases — HarborSite can efficiently and precisely integrate large DNA cargos into genomic safe harbors for robust and durable therapeutic gene expression, with…
-
George Church, PhD
SAB Chair
-
Tina Lebar, PhD
SAB Member
Lybra Bio
Lybra Bio is reshaping the treatment landscape of Autoimmune Skin Diseases. They are developing innovative therapeutics platforms aiming to restore the skin’s immune equilibrium in patients suffering from Autoimmune Skin Diseases. Lybra Bio’s first platform combines clinically validated cytokines loaded into an advanced microneedle patch for superior efficacy and patient compliance while bypassing systemic side…
-
Núria Puigmal, PhD
Founder
-
Jamil R. Azzi, PhD, MD
Academic Co-founder
-
Natalie Artzi, PhD
Academic Co-founder